BALAXI

BALAXI PHARMACEUTICALS

Small Cap NSE: BALAXI
₹437.00
11 (2.58%)
As on 13 August, 2022 | 02:30

Balaxi Pharmaceuticals Share Price

Balaxi Pharmaceuticals Performance

Day Range

  • Low
  • High

52 Week Range

  • Low
  • High
  • Open Price
  • Previous Close
  • Volume

Balaxi Pharmaceuticals Share Returns

  • Over 1 Month 14.78%
  • Over 3 Month 7.68%
  • Over 6 Month -1.48%
  • Over 1 Year -22.79%

Balaxi Pharmaceuticals Key Statistics

P/E Ratio 9.2
PEG Ratio 0.4
Market Cap Cr 437
Price to Book Ratio 3.9
EPS 14.7
Dividend 0
Relative Strength Index 62.61
Money Flow Index 73.27
MACD Signal 10.9
Average True Range 24.53

Balaxi Pharmaceuticals Investment Rating

  • Master Rating:
  • Balaxi Pharmaceuticals has an operating revenue of Rs. 279.39 Cr. on a trailing 12-month basis. An annual revenue growth of 22% is outstanding, Pre-tax margin of 20% is great, ROE of 42% is exceptional. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its 200DMA and around 9% up from its 50DMA. It needs to take out the 200DMA levels and stay above it to make any further meaningful move. It is currently FORMING a base in its weekly chart and is trading around 16% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 95 which is a GREAT score indicating consistency in earnings, a RS Rating of 31 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at C+ which is evident from recent supply seen, Group Rank of 97 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Balaxi Pharmaceuticals Financials
  • Indicator
  • Mar 2022
  • Dec 2021
  • Sep 2021
  • Jun 2021
  • Mar 2021
  • Oper Rev Qtr Cr
  • 21
  • 18
  • 34
  • 29
  • 23
  • Operating Expenses Qtr Cr
  • 17
  • 15
  • 28
  • 24
  • 18
  • Operating Profit Qtr Cr
  • 4
  • 3
  • 5
  • 5
  • 5
  • Depreciation Qtr Cr
  • 0
  • 0
  • 0
  • 0
  • 0
  • Interest Qtr Cr
  • 0
  • 0
  • 0
  • 0
  • 0
  • Tax Qtr Cr
  • 1
  • 1
  • 1
  • 2
  • 1
  • Net Profit Qtr Cr
  • 4
  • 2
  • 4
  • 4
  • 3

Balaxi Pharmaceuticals Technicals

EMA & SMA

Current Price
438.3
12.3 (2.89%)
  • Bullish Moving Average
  • ___
  • 14
  • Bearish Moving Average
  • ___
  • 2
  • 20 Day
  • 413.77
  • 50 Day
  • 403.01
  • 100 Day
  • 413.47
  • 200 Day
  • 448.46
  • 20 Day
  • 411.47
  • 50 Day
  • 389.24
  • 100 Day
  • 403.54
  • 200 Day
  • 448.01

Balaxi Pharmaceuticals Resistance and Support

PIVOT
₹428.12
Resistance
  • First Resistance
  • 431.24
  • Second Resistance
  • 436.47
  • Third Resistance
  • 439.59
Support
  • First Resistance
  • 422.89
  • Second Resistance
  • 419.77
  • Third Resistance
  • 414.54
  • RSI
  • 62.61
  • MFI
  • 73.27
  • MACD Single Line
  • 10.9
  • MACD
  • 13.2

Balaxi Pharmaceuticals Delivery and Volume

  • Period
  • NSE + BSE
    Volume Avg
  • NSE + BSE
    Delivery Volume Avg
  • NSE + BSE
    Delivery Volume %
  • Day
  • 2,327
  • 143,204
  • 61.54
  • Week
  • 3,663
  • 242,417
  • 66.18
  • 1 Month
  • 4,286
  • 270,955
  • 63.22
  • 6 Month
  • 5,020
  • 258,970
  • 51.59

Balaxi Pharmaceuticals Result Highlights

Balaxi Pharmaceuticals Synopsis

NSE-Medical-Generic Drugs

Balaxi Pharmaceutica is involved in the business activities of Other specialized wholesale. Company’s Total Operating Revenue is Rs. 101.29 Cr. and Equity Capital is Rs. 10.00 Cr. for the Year ended 31/03/2022. Balaxi Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 28/09/1942 and has its registered office in the State of Kerala, India. Company’s Corporate Identification Number(CIN) is L25191TG1942PLC121598 and registration number is 000045.
  • Market Cap
  • 438
  • Sales
  • 101
  • Shares in Float
  • 0.27
  • No of funds
  • 3
  • Yield
  • Book Value
  • 7.57
  • U/D Vol ratio
  • 1.3
  • LTDebt / Equity
  • Alpha
  • -0.1
  • Beta
  • 1.15

Balaxi Pharmaceuticals

  • Owner Name
  • Jun-22
  • Mar-22
  • Dec-21
  • Sep-21
  • Promoters
  • 72.86%
  • 72.86%
  • 72.86%
  • Foreign Portfolio Investors
  • 19%
  • 19.28%
  • 19.45%
  • Others
  • 8.14%
  • 7.86%
  • 7.69%

Balaxi Pharmaceuticals Management

  • Name
  • Designation
  • Mr. Ashish Maheshwari
  • Managing Director
  • Mrs. Minoshi Maheshwari
  • Non Executive Director
  • Mr. M Srinivas Rao
  • Independent Director
  • Mr. Purnima Singh Kamble
  • Independent Director
  • Mr. Kunal M Bhakta
  • Independent Director
  • Mr. Gandhi Gamji
  • Independent Director

Balaxi Pharmaceuticals Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Other Analyst Rating

Balaxi Pharmaceuticals Corporate Action

  • Date
  • Purpose
  • Remarks
  • 2022-05-23
  • Audited Results
  • 2022-02-09
  • Quarterly Results
  • 2021-10-28
  • Quarterly Results
  • 2021-07-17
  • Quarterly Results
  • 2021-05-20
  • Audited Results

Balaxi Pharmaceuticals FAQs

What is Share Price of Balaxi Pharmaceuticals ?

Balaxi Pharmaceuticals share price is ₹437 As on 13 August, 2022 | 02:16

What is the Market Cap of Balaxi Pharmaceuticals ?

The Market Cap of Balaxi Pharmaceuticals is ₹437 Cr As on 13 August, 2022 | 02:16

What is the P/E ratio of Balaxi Pharmaceuticals ?

The P/E ratio of Balaxi Pharmaceuticals is 9.2 As on 13 August, 2022 | 02:16

What is the PB ratio of Balaxi Pharmaceuticals ?

The PB ratio of Balaxi Pharmaceuticals is 3.9 As on 13 August, 2022 | 02:16

Q1FY23